Padeliporfin, also known as WST11, is a photosensitizing agent primarily used in photodynamic therapy (PDT) for the treatment of certain types of cancer. It is a synthetic porphyrin derivative that exhibits a strong affinity for tumor tissues, allowing for targeted treatment. Upon activation by specific wavelengths of light, Padeliporfin generates reactive oxygen species (ROS), leading to localized cell damage and apoptosis in cancer cells while sparing surrounding healthy tissue. This selectivity is a key characteristic that enhances its therapeutic potential. Padeliporfin is typically administered intravenously and has been studied for its efficacy in treating conditions such as prostate cancer and other solid tumors. Its pharmacokinetics involve rapid distribution and clearance from the bloodstream, with a tendency to accumulate in neoplastic tissues. Safety profiles indicate that side effects are generally manageable, often limited to localized reactions at the treatment site. Overall, Padeliporfin represents a promising advancement in cancer therapy, leveraging the principles of photochemistry for targeted treatment strategies.

Padeliporfin

759457-82-4: Padeliporfin, also known as WST11, is a photosensitizing agent primarily used in photodynamic therapy (PDT) for the treatment of certain types of cancer. It is a synthetic porphyrin derivative that exhibits a strong affinity for tumor tissues, allowing for targeted treatment. Upon activation by specific wavelengths of light, Padeliporfin generates reactive oxygen species (ROS), leading to localized cell damage and apoptosis in cancer cells while sparing surrounding healthy tissue. This selectivity is a key characteristic that enhances its therapeutic potential. Padeliporfin is typically administered intravenously and has been studied for its efficacy in treating conditions such as prostate cancer and other solid tumors. Its pharmacokinetics involve rapid distribution and clearance from the bloodstream, with a tendency to accumulate in neoplastic tissues. Safety profiles indicate that side effects are generally manageable, often limited to localized reactions at the treatment site. Overall, Padeliporfin represents a promising advancement in cancer therapy, leveraging the principles of photochemistry for targeted treatment strategies.

CAS 759457-82-4

Padeliporfin

Padeliporfin

Ref: 4Z-P-322001